Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma
ChiCTR2100048917Phase 2Recruiting
- Sponsor
- Department of Thoracic Surgery, Tangdu Hospital, Air Force Military Medical University
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Department of Thoracic Surgery, Tangdu Hospital, Air Force Military Medical University. Primary endpoints: Safety, Feasibility of surgery and 8 more. Started Jun 2019; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100048917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048917.